Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients
- 165 Downloads
Inflammatory biomarkers have recently attracted attention as valuable prognosticators and predictors of survival outcomes in many cancers. We describe a new pre-treatment biomarker, expressed as the eosinophil–lymphocytes ratio (ELR) and validate other biomarkers such as the level of circulating eosinophils, neutrophil–lymphocytes ratio (NLR), platelet–lymphocytes ratio (PLR) and systemic immune-inflammatory index (SII) as prognostic factors in cervical cancer (CC) patients.
A retrospective cohort of 151 consecutive patients diagnosed with CC and treated according to the European guidelines with radiotherapy and/or chemotherapy and/or surgery in our institution from 2009 to 2016 were evaluated. Patients were categorized into two different groups based on the optimal cut-off for each biomarker, according to the receiver operating characteristic (ROC) curves. Impact of blood biomarkers on overall survival (OS), cancer-specific survival (CCS) and progression-free survival (PFS) were examined.
Higher values of ELR, eosinophils and age ≥ 50 years were associated with better OS in univariate Cox analysis, while high NLR, PLR, SII, neutrophils ≥ 7.0, Bulky tumor and FIGO stage III–IV at diagnosis were prognosticators of worse survival outcomes. In multivariate analysis, the only factors independently impacting OS were ELR ≥ 0.07 (HR = 0.49, p = 0.048) and FIGO stage III–IV (HR = 2.5, p = 0.018). High PLR and SII were associated with shorter PFR.
Increased values of ELR and eosinophils portend better OS in CC. To our best knowledge, this is the first report describing eosinophils-related biomarker as an independent prognostic factor in CC.
KeywordsSystemic inflammation Cervix cancer Neutrophil–lymphocyte ratio (NLR) Eosinophils Eosinophil–lymphocyte ratio (ELR)
There was no specific funding for this study.
Compliance with ethical standards
Conflict of interest
The authors declare no potential conflicts of interest. Some preliminary results of this study were presented at the 37th ESTRO Annual Meeting held in Barcelona, Spain.
All procedures performed in this study, involving humans participants, were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
All patients included signed the institutional informed consent for treatment and data processing (no specific informed consent was applied).
- 1.National Cancer Institute: SEER Stat Fact Sheets: Endometrial Cancer. http://seer.cancer.gov/statfacts/html/corp.html. Accessed 29 Aug 2018.
- 3.Colombo N, Carinelli S Colombo A, Marini C, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):27–32. https://annonc.oxfordjournals.org/content/23/suppl_7/vii27.fullpdf+html. Accessed 29 Aug 2018.
- 15.Koulis T, Kornaga E, Banerjee R, Phan T, Ghatage P, et al. Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: a retrospective cohort study. Clin Transl Radiat Oncol. 2017;4:51–6. https://doi.org/10.1016/j.ctro.2017.05.001.CrossRefGoogle Scholar
- 19.Scherer T. Tumor associated blood eosinophilia and eosinophilic pleural effusion: case report and review of the literature. Internet J Pulm Med. 1996;1(2).Google Scholar
- 27.Li-Chung Y, Mu-Soon L, Chung-Liang T, et al. Uterine cervical cancer associated with eosinophilic infiltration. J Obstet Gycaecol Res. 1984. https://doi.org/10.1111/j.1447-0756.1984.tb00036.x.Google Scholar